Yahya Tawfik

Dr. Yahya Tawfik

Department of Clinical Pharmacy, King Saud University, Riyadh, Ar Riyāḑ, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
IAIbrahim Alradwan
Ibrahim Alradwan
NFNojoud AL Fayez
Nojoud AL Fayez
MAMohammad Alomary
Mohammad Alomary
AAAbdullah Alshehri
Abdullah Alshehri
AAAlhassan Aodah
Alhassan Aodah
ETEssam Tawfik
Essam Tawfik
Cardiovascular diseases (CVDs) are classed as diseases of aging, which are associated with an increased prevalence of atherosclerotic lesion formation caused by such diseases and is considered as one of the leading causes of death globally, representing a severe health crisis affecting the heart and blood vessels. Atherosclerosis is described as a chronic condition that can lead to myocardial infarction, ischemic cardiomyopathy, stroke, and peripheral arterial disease and to date, most pharmacological therapies mainly aim to control risk factors in patients with cardiovascular disease. Advances in transformative therapies and imaging diagnostics agents could shape the clinical applications of such approaches, including nanomedicine, biomaterials, immunotherapy, cell therapy, and gene therapy, which are emerging and likely to significantly impact CVD management in the coming decade. This review summarizes the current anti-atherosclerotic therapies’ major milestones, strengths, and limitations. It provides an overview of the recent discoveries and emerging technologies in nanomedicine, cell therapy, and gene and immune therapeutics that can revolutionize CVD clinical practice by steering it toward precision medicine. CVD-related clinical trials and promising pre-clinical strategies that would significantly impact patients with CVD are discussed. Here, we review these recent advances, highlighting key clinical opportunities in the rapidly emerging field of CVD medicine.

20 June 2025 in Medicine
Verified
Journal Article
Open access
MAMarwan Alrasheed
Marwan Alrasheed
KAKhalid Alamer
Khalid Alamer
LGLeen Msc Ghonem
Leen Msc Ghonem
AAAbdulrahman A Alsuhibani
Abdulrahman A Alsuhibani
YTYahya Tawfik
Yahya Tawfik
TAThamer A Almangour
Thamer A Almangour
Therapeutic drug monitoring (TDM) is key to optimizing vancomycin therapy, as accurate sampling timing ensures valid drug levels and supports safe, effective clinical decisions. This study aimed to assess the timing accuracy of blood draws for vancomycin TDM, evaluate its clinical implications, and identify predictors of timing errors. A cross-sectional study was conducted at King Saud University Medical City, involving 103 patients from October 2023 to December 2023. The primary outcome was adherence to the blood sampling timing guidelines. Secondary outcomes included clinical cure rates, acute kidney injury incidence, and in-hospital mortality. Of the analyzed samples, 80.6% were improperly timed. Clinical cure rates were significantly higher among patients with correctly timed samples (75%) compared to those with incorrectly timed samples (57.83%). Timely sampling improved cure rates for pulmonary and skin infections (85.71%), while improper timing reduced them to 72.22% and 62.5%, respectively. Improper timing was linked to higher in-hospital mortality (30.12%) and acute kidney injury (15.66%). Multivariate analysis revealed that bacteremia significantly reduced the likelihood of clinical cure (odds ratio = 0.387, 95% confidence interval [0.160, 0.933], P = .035), while 3 times daily dosing significantly increased the odds of correctly timed samples (odds ratio = 5.1, 95% confidence interval [1.125, 23.11], P = .035). This study highlights the critical role of accurate timing in vancomycin TDM for achieving favorable patient outcomes and reducing adverse events. Strengthened institutional protocols and targeted training programs are essential to improve adherence to sampling guidelines and enhance patient safety.

9 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RARawan Fahad Alzaidi
Rawan Fahad Alzaidi
YTYahya Tawfik
Yahya Tawfik
AAAbdullah M. AlRajhi
Abdullah M. AlRajhi
LALama Aldammas
Lama Aldammas
NANora A. Alkhudair
Nora A. Alkhudair
Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML) patients, enabling long-term disease control while highlighting quality of life (QoL) and medication adherence. In Saudi Arabia, data on the relationship of TKI adherence and QoL remains limited. This study evaluated QoL, medication adherence, and their associated factors. A cross-sectional study of adult CML patients on TKI therapy at two Saudi tertiary centers assessed QoL using the EORTC QLQ-CML24 and QLQ-C30, and adherence using the MARS-5. Linear regression analyzed factors associated with global health status, while logistic regression examined factors associated with adherence. Among 100 patients (mean age 46.99 ± 14.26 years) 48% were female and 61% were adherent. Adherent patients had better emotional functioning, with significant lower fatigue, nausea and vomiting, pain, dyspnea, insomnia, and financial difficulties (all p < 0.05). Female sex was independently associated with higher odds of adherence (aOR 3.15, 95% CI 1.05–9.45, p = 0.041). Adherence was associated with a higher global health status score, but not significantly (adjusted β = 4.40, 95% CI -3.81–12.61, p = 0.289). These findings support integrating adherence assessment with patient-reported outcomes and warrant prospective studies to establish this relationship.

30 September 2026 in The American Journal of Medicine
Verified
Journal Article
Closed access
YTYahya Tawfik
Yahya Tawfik
IAIman Ahmed Fathalla Aboelsaad
Iman Ahmed Fathalla Aboelsaad
MNMichael Nelson
Michael Nelson
HYHsin-Jung Yang
Hsin-Jung Yang
LBLeo F. Buckley
Leo F. Buckley

1 May 2025 in INQUIRY: The Journal of Health Care Organization, Provision, and Financing
Verified
Journal Article
Open access
AAAbdullah M. Alhammad
Abdullah M. Alhammad
MAMajidah Aljohani
Majidah Aljohani
BABana Almadi
Bana Almadi
YGYazeed Ghawaa
Yazeed Ghawaa
MAMansour Almuqbil
Mansour Almuqbil
WMWael Mansy
Wael Mansy
Postgraduate programs (PGPs) in pharmacy practice have gained significant importance in recent years, reflecting the evolving roles and expanding responsibilities of pharmacists globally. Understanding the factors that influence the decision to pursue such programs is essential for workforce development and educational planning. This study aimed to assess the motivations and barriers influencing pharmacy interns in Saudi Arabia to pursue PGPs in pharmacy practice. This cross-sectional study was conducted from December 2019 to March 2020 and utilized a validated questionnaire distributed electronically to pharmacy interns (sixth-year pharmacy students) across 3 major pharmacy schools in Saudi Arabia. Data were analyzed using descriptive statistics, chi-square, and Fisher’s exact tests, with a significance level set at a P -value of less than .05. Of the 247 pharmacy interns invited, 157 (62%) completed the survey. Most respondents were female (82.8%) and had an average of 3 clinical and 2 nonclinical advanced pharmacy practice experiences. Approximately 20% intended to pursue PGPs immediately after graduation, while 60% would consider them later. Preferred career paths included hospital pharmacy (31.85%) and regulatory bodies (24.84%). The decision to pursue PGPs in pharmacy practice was influenced by PGP orientation during school, either positively or negatively. The primary motivator cited was the need for further training for future positions, whereas high competition was the most significant barrier. These findings offer valuable insight into pharmacy interns’ perspectives on PGPs, highlighting key motivators and barriers. This understanding can inform future educational strategies and stakeholder efforts aimed at supporting pharmacy interns’ career planning and addressing workforce development needs in pharmacy practice.